Based on the complete genetic analysis of the selected tumour panel, we provide the following results and recommendations:

1) The report includes the variants (mutations) that differ from the human reference genome. For these variants, we indicate whether they are pathogen mutations and are significant regarding the tumorous disease. Furthermore, we also provide the variants of unknown significance (VUS).

2) Interpretation of the results is based on comparing and validating all the found variations with valid biological databases and relevant scientific literature. The data derived from these sources are incorporated into our continuously expanding knowledge base, which is kept up to date by our professional team.

3) Each result is validated by a professional team of molecular pathologists, molecular biologists, and bioinformatics experts. By interpreting the results, we provide support and advice to the oncologist physician, thus helping decision-making:

• We specify whether any known and applied targeted therapy is available for the given tumour and is relevant for the given variant (FDA and/or ESMO approved treatments).
• We also indicate if a therapy is available for the given condition, but it is not recommended.
• Furthermore, we also indicate if a personalised therapy that has not been applied for the given tumour but has been successful in treating other cancers is available for the found significant variant.

In possession of all these information, naturally, choosing the appropriate therapy remains the decision of the physician.